EGFR and cancer: The underlying mechanisms may be that SMET12 specifically binds to EGFR on the surface of cancer cells and CD3 on the surface of lymphocytes to trigger spatial locations of effector T cells near cancer cells and the subsequent generation of immunological synapse, thus activating effector T cells.